20.09 USD
-0.29 (-1.42%)
At close: Jan 29, 2026
20.09 USD
0 (0%)
After Hours: 1/29/2026, 8:00:00 PM
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. These ratings would make PCRX suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- PCRX had positive earnings in 4 of the past 5 years.
- PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of PCRX (1.65%) is better than 81.05% of its industry peers.
- PCRX has a Return On Equity of 2.95%. This is amongst the best in the industry. PCRX outperforms 82.11% of its industry peers.
- PCRX has a Return On Invested Capital of 3.63%. This is amongst the best in the industry. PCRX outperforms 81.58% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- With a decent Profit Margin value of 2.99%, PCRX is doing good in the industry, outperforming 79.47% of the companies in the same industry.
- The Operating Margin of PCRX (8.88%) is better than 81.05% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
- PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
- PCRX has less shares outstanding than it did 1 year ago.
- PCRX has more shares outstanding than it did 5 years ago.
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.83. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- PCRX has a Altman-Z score (1.83) which is comparable to the rest of the industry.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX's Debt to FCF ratio of 3.03 is amongst the best of the industry. PCRX outperforms 90.53% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.83 |
ROIC/WACC0.46
WACC7.86%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 64.74% of the companies in the same industry.
- PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- PCRX has a Quick ratio (3.78) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
- Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.38% on average per year.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 6.76 indicates a rather cheap valuation of PCRX.
- Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.68% of the companies are valued more expensively.
- PCRX is valuated cheaply when we compare the Price/Earnings ratio to 28.39, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 5.78, the valuation of PCRX can be described as very cheap.
- PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.16% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.72, PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.76 | ||
| Fwd PE | 5.78 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 96.32% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, PCRX is valued cheaply inside the industry as 96.32% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.96 | ||
| EV/EBITDA | 5.8 |
4.3 Compensation for Growth
- PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.48
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.76 and the Price/Book (PB) ratio is 1.19.